John Vavricka

Insider Reports History

Location
Boston, MA
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by John Vavricka:

Company Role Class Num Shares Value Price $ Report Date Ownership
Atea Pharmaceuticals, Inc. Chief Commercial Officer Common Stock 82,594 $350,198 $4.24 31 Jan 2026 Direct
Atea Pharmaceuticals, Inc. Chief Commercial Officer Common Stock 82,508 $294,553 $3.57 31 Jan 2026 Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust
Atea Pharmaceuticals, Inc. Chief Commercial Officer Restricted Stock Units 0 $26,775 $3.06 31 Jan 2026 Direct
Atea Pharmaceuticals, Inc. Chief Commercial Officer Stock Option (Right to Buy) 119,520 31 Jan 2026 Direct

Insider Reports Filed by John Vavricka

Symbol Company Period Transactions Value $ Form Type Role Filing Time
AVIR Atea Pharmaceuticals, Inc. 31 Jan 2026 5 -$49,057 4 Chief Commercial Officer 03 Feb 2026, 19:47
AVIR Atea Pharmaceuticals, Inc. 31 Jan 2025 6 -$35,242 4 Chief Commercial Officer 04 Feb 2025, 18:00
AVIR Atea Pharmaceuticals, Inc. 31 Jan 2024 4 -$45,420 4 Chief Commercial Officer 02 Feb 2024, 21:25
AVIR Atea Pharmaceuticals, Inc. 31 Jan 2023 2 $0 4 Chief Commercial Officer 02 Feb 2023, 17:26
AVIR Atea Pharmaceuticals, Inc. 31 Jan 2022 1 $0 4 Chief Commercial Officer 02 Feb 2022, 16:15